Article
22 Aug 2025
Congress Revisits The BIOSECURE Act: Risks For Biotechnology Collaborations With Chinese Entities
AUTHORS CONTENT
Article
08 Aug 2025
Implications Of FDA's "Radical Transparency" Plan For Complete Response Letters
Article
29 Jul 2025
FDA Begins To Accept Nominations For The Commissioner's National Priority Voucher Pilot Program
Article
23 Jun 2025
FDA Announces Commissioner's National Priority Vouchers To Facilitate Expedited Access To Certain Drugs
Article
02 Jun 2025
AI, Medical Products & FDA, Part 1: AI Overview In Life Sciences (Podcast)
Article
14 May 2025
President Trump Issues Executive Order On Regulatory Relief To Promote Domestic Production Of Critical Medicines
Article
22 Apr 2025
Trump Administration Issues Executive Order To Lower Prescription Drug Costs
Article
20 Feb 2025
A First Look At The MAHA Era: Initial Thoughts For Industry Based On The MAHA Commission EO
Article
18 Feb 2025
The DOGE Workforce Optimization EO: Implications For FDA
Article
30 Jan 2025
FDA Finalizes Rule On ACNU Drugs, Signaling Opening For Next-Gen OTC Drugs
Article
27 Dec 2024
Recent SEC Case Against Biotech Company Highlights The Intersection Between FDA Findings And SEC Enforcement
Article
17 Dec 2024
FDA Issues New Draft Guidance For Expedited Program For Serious Conditions — Accelerated Approval Of Drugs And Biologics
Article
13 Nov 2024
The Convergence Of Life Sciences And Artificial Intelligence: Seizing Opportunities While Managing Risk
Article
15 Jul 2024
FDA Issues Revised Draft Guidance On Addressing Misinformation About Medical Devices And Prescription Drugs
Article
11 Jul 2024
When APA Claims Accrue Under Corner Post: Implications For The Life Sciences Industry
Article
03 Jul 2024
Chevron Overturned: What Does It Mean For Life Sciences Companies?
Article
08 May 2024
Five Key Takeaways From FDA's Updated Draft Guidance On Biosimilars Promotion
Article
12 Apr 2024
Life Sciences 2024
Article
24 Feb 2024
Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security
Article
14 Nov 2023
Addressing CBRN Threats And Promoting Responsible AI In Healthcare: Insights From President Biden's AI Executive Order
